Back to discover
Disease
End Stage Liver Disease
Late-stage therapeutic developmentEmerging research
1
Publications
17
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Cardiovascular disease assessment and management in liver transplantation.
Research2024-11-01European heart journal
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Intraoperative Angiotensin 2 for the Prevention of Kidney Injury After Liver Transplant
- Q4 2026Tocotrienol Against the Progression of End Stage Liver Disease
- Q3 2027A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease
- Q4 2027A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
- Q1 2029A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20262026-06-12
Upcoming trial readoutImportant
Results expected Q1 20292026-03-12
Clinical MilestonesViewHide
Results expected
- 2026-06-12Intraoperative Angiotensin 2 for the Prevention of Kidney Injury After Liver TransplantResults expected Q4 2026
- 2026-03-12A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.Results expected Q1 2029
- 2026-02-09Tocotrienol Against the Progression of End Stage Liver DiseaseResults expected Q4 2026
- 2025-11-24A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)Results expected Q4 2027
- 2025-08-08A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver DiseaseResults expected Q3 2027
Activity timeline5
- 2026-06-12ClinicalIntraoperative Angiotensin 2 for the Prevention of Kidney Injury After Liver TransplantResults expected Q4 2026
- 2026-03-12ClinicalA Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.Results expected Q1 2029
- 2026-02-09ClinicalTocotrienol Against the Progression of End Stage Liver DiseaseResults expected Q4 2026
- 2025-11-24ClinicalA 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)Results expected Q4 2027
- 2025-08-08ClinicalA Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver DiseaseResults expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
17
5
7
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes3
- Cardiovascular Diseases1
- End Stage Liver Disease1
- Liver Transplantation1
Leading journals1
- European heart journal1
Leading researchers7
- Accardo C1
- Crespo G1
- Gandolfo C1
- Gruttadauria S1
- Harinstein ME1
- Humar A1
- VanWagner LB1
Affiliations (unnormalised)6
- Heart and Vascular Institute1
- Hospital Clínic1
- University of Catania1
- University of Pittsburgh Medical Center1
- University of Texas Southwestern Medical Center1
- UPMC IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies)1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.